Evidence map›Paper›PMID 24894818›Full record

ArticleBreast cancer research : BCR2014

Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.

Francesca Damiola, Maroulio Pertesi, Javier Oliver, Florence Le Calvez-Kelm, Catherine Voegele, Erin L Young, Nivonirina Robinot, Nathalie Forey, Geoffroy Durand, Maxime P Vallée and 10 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Importance of Germline and Somatic Alterations in HumanInternational journal of molecular sciences · 2023
    Review
  6. Article
  7. NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Article
  13. Cancers · 2021
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 5 countries.

Francesca Damiola
Maroulio Pertesi
Javier Oliver
Florence Le Calvez-Kelm
Catherine Voegele
Erin L Young
Nivonirina Robinot
Nathalie Forey
Geoffroy Durand
Maxime P Vallée
Kayoko Tao
Terrell C Roane
Gareth J Williams
John L Hopper
Melissa C Southey
Irene L Andrulis
Esther M John
David E Goldgar
Fabienne Lesueur
Sean V Tavtigian
Centre International de Recherche sur le Cancer · FRHuntsman Cancer Institute · USUniversity of Utah · USCancer Prevention Institute of California · USCentre de Recherche en Cancérologie de Lyon · FRInserm · FRLawrence Berkeley National Laboratory · USSeoul National University · KRThe University of Texas at Austin · USUniversity of Melbourne · AUUniversity of Toronto · CA

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Breast Cancer Family Registry CohortUM1CA164920 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI ANDRULIS, IRENE, BUYS, SAUNDRA S · 2012 to 2017
$12.7M
COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISKR01CA121245 · NCI · UNIVERSITY OF UTAH · PI TAVTIGIAN, SEAN VAHRAM · 2007 to 2021
$4.9M
CIHRNCI NIH HHS P30 CA042014NCI NIH HHS R01 CA121245NCI NIH HHS UM1 CA164920World Health Organization 001
6 · The paper itself

Abstract

introductionThe MRE11A-RAD50-Nibrin (MRN) complex plays several critical roles related to repair of DNA double-strand breaks. Inherited mutations in the three components predispose to genetic instability disorders and the MRN genes have been implicated in breast cancer susceptibility, but the underlying data are not entirely convincing. Here, we address two related questions: (1) are some rare MRN variants intermediate-risk breast cancer susceptibility alleles, and if so (2) do the MRN genes follow a BRCA1/BRCA2 pattern wherein most susceptibility alleles are protein-truncating variants, or do they follow an ATM/CHEK2 pattern wherein half or more of the susceptibility alleles are missense substitutions?

methodsUsing high-resolution melt curve analysis followed by Sanger sequencing, we mutation screened the coding exons and proximal splice junction regions of the MRN genes in 1,313 early-onset breast cancer cases and 1,123 population controls. Rare variants in the three genes were pooled using bioinformatics methods similar to those previously applied to ATM, BRCA1, BRCA2, and CHEK2, and then assessed by logistic regression.

resultsRe-analysis of our ATM, BRCA1, and BRCA2 mutation screening data revealed that these genes do not harbor pathogenic alleles (other than modest-risk SNPs) with minor allele frequencies>0.1% in Caucasian Americans, African Americans, or East Asians. Limiting our MRN analyses to variants with allele frequencies of <0.1% and combining protein-truncating variants, likely spliceogenic variants, and key functional domain rare missense substitutions, we found significant evidence that the MRN genes are indeed intermediate-risk breast cancer susceptibility genes (odds ratio (OR)=2.88, P=0.0090). Key domain missense substitutions were more frequent than the truncating variants (24 versus 12 observations) and conferred a slightly higher OR (3.07 versus 2.61) with a lower P value (0.029 versus 0.14).

conclusionsThese data establish that MRE11A, RAD50, and NBN are intermediate-risk breast cancer susceptibility genes. Like ATM and CHEK2, their spectrum of pathogenic variants includes a relatively high proportion of missense substitutions. However, the data neither establish whether variants in each of the three genes are best evaluated under the same analysis model nor achieve clinically actionable classification of individual variants observed in this study.

Indexed as

Genetic Predisposition to DiseaseAcid Anhydride HydrolasesAdultAmino Acid SubstitutionAtaxia Telangiectasia Mutated ProteinsBase SequenceBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCase-Control StudiesCell Cycle ProteinsCheckpoint Kinase 2DNA-Binding ProteinsDNA Breaks, Double-StrandedDNA RepairDNA Repair EnzymesAcid Anhydride HydrolasesAtaxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCell Cycle ProteinsCheckpoint Kinase 2CHEK2 protein, humanDNA-Binding ProteinsDNA Repair EnzymesMRE11 Homologue ProteinMRE11 protein, humanNBN protein, humanNuclear ProteinsProtein IsoformsRAD50 protein, human

Identifiers

PMID24894818
PMCPMC4229874
OpenAlexW2159574432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.